Abstract 798
Background
TGCT is a rare, locally aggressive neoplasm of the joint/tendon sheath associated with colony-stimulating factor 1 (CSF1) overexpression. No systemic therapy is approved. Pex, a selective inhibitor of CSF1 receptor, KIT, and FLT3-ITD, showed tumor responses in TGCT in 3 phase I studies, and significant response by Response Evaluation Criteria in Solid Tumors v1.1 (39% vs 0%; P < 0.0001) and improved functional outcomes vs placebo in a phase III study (ENLIVEN, NCT02371369). Here we report treatment-emergent hepatic ARs across TGCT studies.
Methods
Patients (pts) ≥18 y had symptomatic, unresectable TGCT; surgery was not recommended and/or was associated with potentially worse function or severe morbidity. Hepatic ARs were assessed by type and magnitude of liver test abnormalities.
Results
In 130 pts assessed for hepatic ARs from the ENLIVEN and phase I extension (PLX108-01, NCT01004861) studies, mean Pex duration was 75 wk (range, 2.14-259.14); 10 additional Pex-treated pts from 2 other phase I studies are included in the table (N = 140). Hepatic ARs were of 2 types: (1) aminotransferase elevations, which were frequent, dose-dependent, and related to CSF1 receptor inhibition, and (2) mixed or cholestatic hepatotoxicity, which was uncommon, idiosyncratic, and rarely serious (Table). All serious hepatic ARs developed in the first 8 wk of treatment. Four serious but nonfatal mixed and cholestatic cases with increased bilirubin (1 ductopenia) resolved after 1-7 mo. In non-TGCT pts (N = 658), 2 severe cases of liver toxicity (1 leading to liver transplant, 1 death with ongoing cholestasis and tumor progression) were observed with Pex.Table:
1696P
Frequency of Liver Test Abnormalities | |||||
Clinical Parameter | Phase III ENLIVEN Randomized (1000 mg/d)* n = 61 | Phase III ENLIVEN Crossover (800 mg/d)* n = 30 | Phase I PLX108-01 TGCT Cohort (1000 mg/d)* n = 39 | Other Phase I† (600 or 800 mg/d)* n = 10 | Total‡N = 140 |
Aminotransferase elevations, n (%) | |||||
ALT or AST | |||||
≥1 to < 3 × ULN ≥3 to < 5 × ULN ≥5 to < 10 × ULN ≥10 to < 20 × ULN ≥20 × ULN | 48 (79) 8 (13) 7 (11) 3 (5) 2 (3) | 21 (70) 3 (10) 2 (7) 1 (3) 0 | 27 (69) 4 (10) 2 (5) 2 (5) 0 | 6 (60) 2 (20) 0 0 0 | 102 (73) 17 (12) 11 (8) 6 (4) 2 (1) |
Mixed or cholestatic hepatotoxicity, n (%) | |||||
ALT or AST ≥3 ×, TBIL ≥2 ×, and ALP ≤2 × ULN (Hy’s law) | 0 | 0 | 0 | 0 | 0 |
ALT or AST ≥3 ×, TBIL ≥2 ×, and ALP ≥2 × ULN | 3 (5) | 0 | 1 (3)§ | 1 (10) | 5 (4)§ |
TBIL ≥2 × ULN (in absence of ALT ≥3 × or ALP >2 × ULN) | 0 | 0 | 1 (3) | 0 | 1 (1) |
Pex starting dose.
†Includes 1 TGCT pt receiving 600 mg/d in NCT02734433 and 9 TGCT pts receiving 800 mg/d in NCT03291288. ‡Mean Pex duration of all studies was 71 wk (range, 2.14-259.14).
§Includes 1 TGCT pt with a single time-point elevation of TBIL considered unrelated to treatment. ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBIL = total bilirubin; ULN = upper limit of normal.
Conclusions
Pex is the first systemic therapy assessed in a randomized placebo-controlled study showing significantly improved tumor response and clinical benefit in locally advanced TGCT. With liver test monitoring, Pex may offer a relevant treatment option for select pts with symptomatic TGCT.
Clinical trial identification
NCT02371369, NCT02734433, NCT03291288, NCT01004861.
Editorial acknowledgement
Phillip Giannopoulos, PhD, SciStrategy Communications.
Legal entity responsible for the study
Overall abstract: Daiichi Sankyo, Inc. Individual studies: NCT02371369 – Daiichi Sankyo, Inc., NCT01004861 – Plexxikon Inc., NCT02734433 – Daiichi Sankyo Co., Ltd., NCT03291288 – Daiichi Sankyo, Inc.
Funding
Overall abstract funded by Daiichi Sankyo, Inc. Individual studies: NCT02371369 – Daiichi Sankyo, Inc., NCT01004861 – Plexxikon Inc., NCT02734433 – Daiichi Sankyo Co., Ltd., NCT03291288 – Daiichi Sankyo, Inc.
Disclosure
S. Bauer: Advisory / Consultancy, Research grant / Funding (self): Blueprint Medicines; Advisory / Consultancy: Deciphera; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self): PharmaMar; Advisory / Consultancy: ADC Therapeutics; Advisory / Consultancy, CME-educational presentations: Lilly; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: Bayer; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: Nanobiotix; Research grant / Funding (self), Investigator-initiated trial: Incyte; Officer / Board of Directors, Member of External Advisory Board for "Off-label use in oncology": Federal Ministry of Health. J.H. Lewis: Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Gilead. H. Gelderblom: Research grant / Funding (institution), Licensing / Royalties: Daiichi Sankyo; Licensing / Royalties: Boehringer Ingelheim; Licensing / Royalties: Pfizer; Licensing / Royalties: Novartis; Licensing / Royalties: PharmaMar; Licensing / Royalties: Five Prime; Licensing / Royalties: Amgen. M. van de Sande: Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo. S. Stacchiotti: Honoraria (self): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): PharmaMar; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Epizyme; Advisory / Consultancy: Immunedesign; Advisory / Consultancy: Maxivax; Advisory / Consultancy, Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Advenchen; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer. J.H. Healey: Advisory / Consultancy: Stryker; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: Agios; Research grant / Funding (self): Illuminoss. W.D. Tap: Shareholder / Stockholder / Stock options: Certis Oncology Solutions; Shareholder / Stockholder / Stock options: Atropos Therapeutics; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: EMD Serono; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Immune Design; Honoraria (self), Advisory / Consultancy: Adaptimmune; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy: Blueprint; Honoraria (self), Advisory / Consultancy: Loxo; Honoraria (self), Advisory / Consultancy: GlaxoSmithKline; Honoraria (self), Advisory / Consultancy: Agios Pharmaceuticals; Honoraria (self), Advisory / Consultancy: NannoCarrier; Advisory / Consultancy: Plexxikon Pharmaceuticals; Licensing / Royalties, Companion Diagnostic for CDK4 inhibitors: Companion Diagnostic for CDK4 inhibitors. A.J. Wagner: Honoraria (self): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Five Prime; Advisory / Consultancy: Nanosphere; Research grant / Funding (institution): Plexxikon; Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Celldex; Research grant / Funding (institution): Aadi Bioscience. A. Lopez Pousa: Research grant / Funding (self): CEBIOTEX. M. Druta: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai. C. Lin: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Roche; Travel / Accommodation / Expenses: BeiGene; Research grant / Funding (institution): Daiichi Sankyo. A. Yver: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo. D.E. Shuster: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo; Shareholder / Stockholder / Stock options: Pfizer; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb; Shareholder / Stockholder / Stock options: Merck; Shareholder / Stockholder / Stock options: Regeneron; Shareholder / Stockholder / Stock options: Exelixis. J. McGill: Advisory / Consultancy, Full / Part-time employment: Daiichi Sankyo. X. Gu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo; Shareholder / Stockholder / Stock options, Full / Part-time employment, Immediate family member: PTC Therapeutics. L.D. DeLeve: Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: AbbVie; Advisory / Consultancy: SeaGen; Licensing / Royalties, Univ and I have filed provisional patent: University of Southern California. All other authors have declared no conflicts of interest.
Resources from the same session
5939 - Matrix metalloproteinases and their tissue inhibitors genes abnormal DNA methylation in breast cancer
Presenter: Olga Simonova
Session: Poster Display session 1
Resources:
Abstract
2703 - Uveal melanoma cell lines depend on multiple signaling pathways for survival
Presenter: John Park
Session: Poster Display session 1
Resources:
Abstract
4849 - XAF1 and ZNF313 complex stimulates ER stress-induced apoptosis via direct GRP78 inhibition.
Presenter: Sungchan Jang
Session: Poster Display session 1
Resources:
Abstract
4801 - XAF1 assembles a destructive complex to induce BRCA1-mediated apoptosis via suppressing ERa and switching estrogen function
Presenter: Seung-hun Jang
Session: Poster Display session 1
Resources:
Abstract
3416 - Cancer associated fibroblasts promote cancer progression via Wnt2 secretion in colorectal cancer
Presenter: Hideaki Karasawa
Session: Poster Display session 1
Resources:
Abstract
4273 - Paired-related homeobox 1 overexpression promotes invasion and metastasis and is a prognostic factor for worse disease-free survival in patients with lung cancer
Presenter: Jung-jyh Hung
Session: Poster Display session 1
Resources:
Abstract
4241 - LncRNA-GC1 contributes to gastric cancer chemo-resistance through inhibition of miR-551b-3p and the overexpression of dysbindin
Presenter: Xin Guo
Session: Poster Display session 1
Resources:
Abstract
5388 - GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
5208 - Characterisation of growth hormone signal transduction in primary melanoma cell lines
Presenter: Karla Sousa
Session: Poster Display session 1
Resources:
Abstract
3156 - LAPTM5 protein can regulate TGF-β mediated MAPK and Smad signaling pathways in ovarian cancer cell
Presenter: Yan Gao
Session: Poster Display session 1
Resources:
Abstract